Has the Failure to Agree on Pathogen Sharing Already Rendered the WHO Pandemic Treaty Meaningless?

The prevailing narrative surrounding the World Health Organization’s Pandemic Agreement is that the world finally learned its lesson. When the World Health Assembly adopted the core text of the treaty in May 2025, global headlines celebrated a new era of international cooperation—a legally binding shield designed to prevent the catastrophic failures of the COVID-19 era. But this assumption fundamentally misunderstands how international health law actually operates. The treaty, as it stands today, is merely an architectural blueprint missing its engine. Without its central operational mechanism, the agreement currently lacks the legal teeth to change how nations respond to a fast-moving outbreak.[1][6]

That missing engine is the Pathogen Access and Benefit-Sharing (PABS) system. Without it, the Pandemic Agreement is largely a collection of aspirational norms regarding surveillance and health system strengthening. The core premise of PABS is a transactional grand bargain: countries that detect a novel, dangerous pathogen must rapidly share physical samples and digital sequence information with the global scientific community. In exchange, the pharmaceutical companies and wealthy nations that use that data to develop vaccines, therapeutics, and diagnostics must guarantee equitable access to those resulting products for the developing world.[1][5]

Yet, as the seventh meeting of the Intergovernmental Working Group concluded in Geneva in July 2026, that grand bargain remains paralyzed by fundamental disagreements. The failure to finalize the PABS annex has not just delayed the treaty’s operational rollout; it has exposed a structural rift in global health governance. This deadlock threatens to render the entire agreement meaningless before it even enters into force, leaving the international community exactly where it was in early 2020: reliant on voluntary charity rather than binding obligations.[1][2]

To understand the stakes, one must look at the legal reality of "viral sovereignty." Under the Convention on Biological Diversity and its Nagoya Protocol, genetic resources—including pathogens—are considered the sovereign property of the nation where they are discovered. If a new virus emerges in a tropical ecosystem, that country has the established legal right to withhold the pathogen from the international community until a bilateral benefit-sharing agreement is reached with the researchers or companies seeking access. This legal framework was originally designed to protect biodiversity, but its application to public health has fundamentally altered how scientists track emerging diseases.[4]

During a fast-moving outbreak, bilateral negotiations are a death sentence for rapid response. The PABS system was designed to bypass this bottleneck by creating a single, multilateral mechanism. Instead of negotiating country-by-country, researchers would share data instantly through WHO-coordinated networks. In return, users of that data would sign standardized, legally binding contracts committing a percentage of their production or revenue to a global equity pool, ensuring that the benefits of scientific innovation reach the populations that provided the initial data.[4][6]

The evidence supporting the need for such a system is overwhelming. During the COVID-19 pandemic, researchers in South Africa rapidly sequenced and shared the Omicron variant, fulfilling their scientific duty to the global community. In response, they saw their country hit with immediate travel bans while simultaneously struggling to secure the very vaccines that were developed using their open-source data. The PABS annex was explicitly drafted to prevent this exact scenario of exploitation from repeating.[3][6]

However, the negotiations have fractured into two competing visions. The Africa Plus Group, representing nations that frequently source these pathogens but lack domestic manufacturing capacity, has championed a "federated" model. This approach demands strict end-to-end traceability of biological materials and digital sequence information. It structurally conditions access to the data on binding, upfront commitments to share the resulting medical products, ensuring that no entity can download a viral sequence without legally agreeing to the equity terms.[2]

The argument underpinning the federated model is straightforward: voluntary mechanisms failed the Global South during the last crisis, and only ironclad contractual obligations can ensure equity. If a European pharmaceutical giant uses an African viral sequence to develop a multi-billion-dollar vaccine, the source region must be guaranteed a predefined share of those doses at affordable prices. For these nations, the data is a sovereign asset, and giving it away for free is no longer a viable policy.[2][6]

On the other side of the table, the European Union and allied developed nations have pushed for a "hybrid" model. This proposal blends mandatory WHO-controlled sharing with voluntary national processes. It argues that overly restrictive traceability requirements and heavy mandatory contributions will stifle the very innovation the world relies on during a crisis. The hybrid model seeks to maintain open access to digital sequence information while encouraging, rather than strictly mandating, benefit-sharing contributions.[2][5]

The pharmaceutical industry has strongly backed this lighter-touch approach, warning that a purely transactional system could deter companies from utilizing the PABS network altogether. Industry representatives argue that if the cost of accessing a viral sequence is a mandatory forfeiture of intellectual property or a massive product donation, companies might simply wait for the data to leak through other channels or rely entirely on domestic surveillance, ultimately slowing down the development of life-saving countermeasures.[5]

This is where the uncertainty deepens into a genuine systemic risk. If the PABS annex imposes rules that are too strict, the private sector may balk, crippling the rapid development of vaccines. But if the rules are too weak, developing nations may simply refuse to share their pathogens, invoking their sovereign rights under the Nagoya Protocol. This would blind the global surveillance network at the exact moment a new threat emerges, preventing anyone from developing a vaccine in the first place.[3][6]

The legal complexity is further compounded by overlapping international frameworks that threaten to entangle researchers in red tape. In parallel to the WHO negotiations, parties to the Convention on Biological Diversity have established a multilateral mechanism for Digital Sequence Information, known as the Cali Fund. This fund expects large companies using publicly available genetic data to pay a percentage of their revenue into a global biodiversity pool, creating a separate financial obligation for the exact same scientific activities governed by the WHO.[4]

If the WHO’s PABS system and the Cali Fund are not perfectly harmonized, researchers and manufacturers could face a labyrinth of competing obligations. Determining whether a single viral sequence is governed by the WHO treaty, the Cali Fund, or dozens of national access laws would require immense legal resources. Experts warn that this regulatory friction will create a chilling effect on rapid scientific collaboration, punishing the researchers who attempt to play by the rules.[4][6]

The extension of the PABS negotiations into late 2026 highlights the intractability of these issues. While diplomats point to incremental progress—such as a growing consensus that benefit-sharing should apply not just during full-blown pandemics, but also during routine public health emergencies—the core mathematical divide over mandatory product allocations remains unresolved. The fundamental question of who owns a virus and who profits from its cure is still unanswered.[2]

Ultimately, a Pandemic Agreement without a functional PABS annex is a return to the precarious status quo. It leaves the world relying on the goodwill of wealthy nations and the voluntary cooperation of the pharmaceutical industry—the exact paradigm that the treaty was commissioned to replace. Without a binding mechanism to enforce equity and mandate the distribution of medical countermeasures, the grand promises made in the aftermath of COVID-19 risk becoming historical footnotes, offering no real protection to the world's most vulnerable populations.[3][6]

The coming months of negotiation will determine whether the international community can bridge the gap between sovereign equity and rapid innovation. Until that grand bargain is struck and the PABS annex is signed, the WHO Pandemic Agreement remains a profound statement of shared values, but not yet a functional tool for global survival. The clock is ticking, and the next pathogen will not wait for the diplomats to finish their paperwork.[6]